Chenyue Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9714140/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8+ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma. International Journal of General Medicine, 2022, Volume 15, 4209-4220.	1.8	3
2	LHPP suppresses tumorigenesis of intrahepatic cholangiocarcinoma by inhibiting the TGFβ/smad signaling pathway. International Journal of Biochemistry and Cell Biology, 2021, 132, 105845.	2.8	11
3	Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors. Lung Cancer, 2021, 154, 221-223.	2.0	4
4	The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores. Lung Cancer, 2021, 154, 214-215.	2.0	1
5	Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials. Signal Transduction and Targeted Therapy, 2021, 6, 141.	17.1	0
6	The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration. Journal of Translational Medicine, 2021, 19, 259.	4.4	0
7	Genetic alternations and immune characteristics in patients with small cell lung cancer. Cancer Communications, 2021, 41, 1075-1078.	9.2	6
8	Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting. Journal of Translational Medicine, 2021, 19, 385.	4.4	2
9	Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 732841.	2.8	1
10	Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Frontiers in Genetics, 2021, 12, 717319.	2.3	10
11	Integrative analysis of genomic alteration, immune cells infiltration and prognosis of lung squamous cell carcinoma (LUSC) to identify smoking-related biomarkers. International Immunopharmacology, 2020, 89, 107053.	3.8	11
12	TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti TLA4 treatment. Cancer Medicine, 2020, 9, 7151-7160.	2.8	33
13	Patients With BRAF-Mutant NSCLC May Not BenefitÂFrom Immune Checkpoint Inhibitors: A Population-Based Study. JTO Clinical and Research Reports, 2020, 1, 100006.	1.1	8
14	CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. Cancer Cell International, 2020, 20, 583.	4.1	31
15	KEAP1-NFE2L2–Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis. Journal of Thoracic Oncology, 2020, 15, e85-e86.	1.1	9
16	Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types. JAMA Network Open, 2020, 3, e202950.	5.9	71
17	Construction of immune-related and prognostic IncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples. Aging, 2020, 12, 9868-9881.	3.1	9
18	Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma. Aging, 2020, 12, 17288-17294.	3.1	7

CHENYUE ZHANG

#	Article	IF	CITATIONS
19	Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years. Discovery Medicine, 2018, 25, 91-98.	0.5	6
20	Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma. OncoTargets and Therapy, 2017, Volume 10, 1441-1449.	2.0	33
21	Prognostic nutritional index serves as a predicative marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 6417-6423.	2.0	33
22	Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study. Oncotarget, 2016, 7, 85603-85612.	1.8	3
23	Na+/K+-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma. Oncotarget, 2015, 6, 28183-28193.	1.8	39